BACKGROUND: @entity13366 ( @entity13366 ) with peanut changes clinical and immune responses in most peanut-allergic individuals, but the response is highly variable. OBJECTIVE: We sought to examine the component-specific effects of peanut @entity13366 and determine whether peanut component testing could predict the outcome of a double-blind, placebo-controlled food challenge (DBPCFC) after 12 months of peanut @entity13366 . METHODS: We included 33 subjects who underwent peanut @entity13366 with a DBPCFC of 2500 mg of peanut protein performed after 12 months on therapy. Plasma samples from baseline and after 12 months of peanut @entity13366 were assayed using ImmunoCAP for IgE and IgG4 against whole peanut, Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9. RESULTS: Following 12 months of @entity13366 , 10 subjects (30%) passed the DBPCFC without symptoms and were considered desensitized. Subjects that failed the DBPCFC tolerated a median of 460 mg peanut protein (range: 10-1710 mg). The desensitized group had significantly lower baseline levels of IgE against peanut (median 40.8 vs 231 kUA /L, p = 0.0082), Ara h 2 (median 17 vs 113 kUA /L, p=0.0082), and Ara h 3 (median 0.3 vs 8.5 kUA /L, p = 0.0396). ROC curves indicated that baseline IgE against peanut and Ara h 2 were equally effective at discriminating between the two groups (AUC = 0.7957, p = 0.007752 for both). CONCLUSION AND CLINICAL RELEVANCE: In this cohort of subjects undergoing @entity13366 for @entity16244 , lower baseline levels of IgE against Ara h 2, Ara h 3, and peanut were associated with successful desensitization. This article is protected by copyright. All rights reserved.

Utility of component analyses in subjects undergoing sublingual immunotherapy for XXXX .

@entity13366 :: ('MESH:D013362', 'Disease') :: ['SLIT', 'Sublingual immunotherapy'] @entity16244 :: ('MESH:D021183', 'Disease') :: ['peanut allergy']
@entity16244 :: (MESH:D021183,Disease) :: ['peanut allergy']
